Amersin Life Sciences: Contract with China's International Tsunami Relief Program

New York, NY (PRWEB via PR Web Direct) January 24, 2005 -- Amersin Life Sciences Corporation (OTCBB: AMLS), announced today that it's subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Co. Ltd., has entered into a sales contract valued at 6.4 million RMB with the Ministry of Health's China Medicine and Technology Foreign Co-operation Co. Ltd.

"This contract is to supply pharmaceuticals to aid Sri Lanka as part of the China's tsunami relief program," said Mr. Yiqing Wan, President of the Amersin subsidiary, "we are very pleased to be selected as a supplier and to be part of this international tsunami relief effort. It further illustrates our strong product reputation and relationships with governmental and non-governmental organizations (NGO's) alike.

We would of course prioritize to participate further if called upon or opportunities arise to support other initiatives.                                            

About Amersin Life Sciences Corporation:

Amersin is engaged in the acquisition and vertical integration of operating subsidiaries and controlling joint venture interests in China to include all facets of pharmaceutical life sciences from research through raw materials and dosage form production to distribution. Its recent acquisition of a controlling interest in the profitable Hubei Tongji Benda Ebei Pharmaceutical Co. subsidiary is a cornerstone in its plan to expand through strategic acquisition and vertical integration to become one of the leading American corporations to profit from the burgeoning life sciences sector in China.